AstraZeneca Pharma India growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+32.6%	+31.4%
EBITDA	+3.2%	+16.6%
Net Income	+62.1%	+23.6%
EPS (adj.)	+62.1%	+23.6%
Total Assets	+31.0%	+26.4%
Total Equity	+13.3%	+14.0%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ASTRAZEN₹6,237.00

AstraZeneca Pharma India Limited

· Pharma & Health

₹ CrorePeersSANOFICONR PGHL SANOFI SENORES INNOVACAP MOREPENLAB IOLCP FDCMcap ₹15,593 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+32.6	+31.4
EBITDA	+3.2	+16.6
Net Income	+62.1	+23.6
EPS (adj.)	+62.1	+23.6
Total Assets	+31.0	+26.4
Total Equity	+13.3	+14.0

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.